SCHEMBL25210468

SCHEMBL25210468

Cc1[nH]nc(-c2ccc(F)cc2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC6 Q9UBN7 1/20 0.44
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR1E P28566 1/20 0.44
HTR7 P34969 1/20 0.44
HTR2B P41595 1/20 0.44
HTR6 P50406 1/20 0.44
ALPL P05186 1/20 0.42
AXL P30530 1/20 0.41
KEAP1 Q14145 1/20 0.41
ERBB2 P04626 1/20 0.41
MAP2K4 P45985 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17054307 0.83 MEN1 (0.53) ALDH1A1SMN1; SMN2HTR1DHTR2AHTR2C
SCHEMBL20075104 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HDAC6HTR1AHTR1D
SCHEMBL15779008 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HTR1AHTR1DHTR2A
SCHEMBL24052103 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HTR1AHTR1DHTR2A
SCHEMBL16200385 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HTR1AHTR1DHTR2A
SCHEMBL17054325 0.80 IKBKB (0.53) HTR1DHTR2AHTR2CHTR1EHTR7
SCHEMBL21501581 0.80 DYRK1A (0.38) ALDH1A1SMN1; SMN2HTR1DHTR2AHTR2C
SCHEMBL11622606 0.79 AKT2 (0.53) ALDH1A1SMN1; SMN2ALPLKDM4EKMT2A
SCHEMBL14370266 0.78 CYP1A2 (0.47) ALDH1A1SMN1; SMN2HDAC6HTR1AHTR1D
SCHEMBL13162473 0.78 LRRK2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026762-A1 FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-01-23 US disclosed
EP-4441034-A1 FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Merck Sharp & Dohme LLC (US) 2024-10-09 EP disclosed
WO-2023101895-A1 FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026762-A1 FUSED PYRAZOLE UREA ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, UGCG ALDH1A1 2176/4885SMN1; SMN2 1330/4885HDAC6 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.